Day Two

• Exploring the development and application of fully humanised in vivo systems to replicate human immune responses and tumour biology, enabling robust evaluation of immunotherapies
• Demonstrating how this humanised model yielded clinically relevant data in diseases such as lymphoma and myeloma, with a focus on T cell engagers and co-stimulatory pathways
• Discussing how these models complement advanced in vitro systems and support decision-making across the drug development pipeline, from early efficacy to translational validation

• Development and application of organoids and PDX models to study adaptive responses to targeted therapies and immunotherapies in prostate cancer
• Elucidating which model from organoids and PDX mice is more representative of prostate cancer
• Using clinical data from Phase I and II trials to better understand mechanism of resistance and pathology to develop better therapeutic strategies with a focus on enhancing clinical relevance and therapeutic precision

• Presentation details to be announced

Witness some of the latest and greatest research in the tumour modelling field in this spotlight poster session! Visit the website for T&Cs for submitting a poster.

• Understanding the different tumour models used in drug discovery and development across the field
• Reiterating the importance of assessing animal welfare impact when selecting models, with strict parameters to ensure the science can be obtained without excessive animal burden
• Discussing how we can continue to incorporate the 3Rs into our workflows better

• Presentation details to be announced

• Leveraging patient-derived organoids (PDOs) and genetically engineered mouse model (GEMM)-derived organoids to enhance the predictive power of cancer immunotherapy studies
• Overcoming technical and biological hurdles in the development of relevant advanced stage and metastatic mouse models to better mimic human disease progression
• Integrating experimental biology with computational modelling to align preclinical outputs with clinical datasets, facilitating the creation of predictive in silico frameworks for translational oncology

• Informing the clinical starting dose for novel CAR-T cells by benchmarking against clinically-utilized CAR-T products in mouse models
• Optimizing the translational approach for the allometric scaling of CAR-T cellular kinetics between mouse models and patients
• •Uncovering the translational relevance and predictability of different preclinical mouse models through a mathematical modeling approach for CAR-T cells

• Applying wt and humanised in vivo platforms to assess therapeutic performance of ADCC-inducing antibodies across solid and liquid tumour types, including CLL
• Identifying and validating biomarkers from head and neck cancer patient datasets, with correlation to preclinical mouse models
• Leveraging humanised mice to bridge mechanistic insights and clinical relevance, supporting the development of targeted immunotherapies with translational impact

• Understanding the rationale behind selecting the most relevant and translatable in vivo models
• Leveraging these models to better understand safety and efficacy of CAR-T cells in solid tumours
• Understanding the safety endpoints of the model to advance the clinical translations of this CAR-T therapy

The winning poster will be announced at this time. The winner will receive their award, and have their poster showcased on our website as a downloadable file.

• Highlighting the rationale behind selecting the model
• Identifying predictive biomarkers that correlate with drug response, aiding in patient stratification and personalised treatment
• Leveraging findings to empower dosing strategies and spotlighting future directions

• Highlighting the background of fibroblast activation protein (FAP)-enabled pre|CISION®-peptide drug conjugates (PDCs) and the rationale for model selection
• Sharing best practices for developing co-cultures of tumour cells and human primary FAP+ fibroblasts to assess bystander activity of PDCs in physiologically relevant systems
• Characterising PDCs using CDX, PDX models, and spheroid co-cultures to better understand their mechanism of action

• Addressing the limitations of traditional mouse models for gamma-delta T cell studies and strategies for identifying or developing humanised mouse models
• Optimising experimental variables—such as cell source, transfer method, and tumour type—to align with specific therapeutic objectives, from efficacy assessment to immune profiling
• Implementing robust, foundational assays to evaluate gamma-delta T cell presence and activity following therapeutics, ensuring reliable data generation and efficient model characterisation